Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and neck cancer
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Proceedings of the National Academy of Sciences, Volume 123, Number 13, March 2026.
SignificanceHere, we identify a molecular pathway that drives cisplatin resistance in head and neck squamous cell carcinoma (HNSCC). Angiopoietin-like angiogenic factor 4 (ANGPTL4) engages Neuropilin1 to activate ABL1, which in turn phosphorylates and…
